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WHAT IS NEW IN BLADDER 
CANCER IMAGING
Jelle O. Barentsz, MD, PhD, J. Alfred Witjes, MD, PhD, 
and Jef H J. Ruijs, MD, PhD
C arc inom a of the u r in a ry  b lad d er, after 
prostate cancer, is the m ost common malig­
nan t tum or of the urinary  tract in m en and  
w om en and  accounts for 2 % of all m alignan­
cies. In 1993, in the U nited States 52,300 cases 
w ere registered. A lthough this num ber is still 
increasing because of aging of the population, 
sm oking behavior (the most im portant single 
risk factor) is also an obvious influence. For 
exam ple , b la d d e r  cancer m orta lity  has d e ­
c reased  since 1990 because  of changes in  
sm oking behavior in the male Dutch popula­
tion for successive b irth  cohorts after 1930 
(L iem eney LALM , W itjes JA, un p u b lish ed  
data). The m ortality  in  the United States in 
1993 was 9900. B ladder cancer is seen p re­
dom inantly  in elderly m en and the male to 
female ratio is 4:1.
A bout 90% to 95% of urinary bladder m a­
lignancies are tran s itio n a l cell carcinom as, 
and  the rem aining 5% to 10% consist of squa­
m ous cell carcinomas and adenocarcinomas 
and  a small num ber of sarcomas and métasta­
sés from  other p rim ary  tumors. About two 
th irds of the tum ors are superficial (<  pT2 ) 
and are usually pap illary .15 One third of the 
tum ors show infiltration into or beyond the 
m uscular layer of the b ladder wall.
The initial treatm ent and prognosis largely 
are determ ined by  the dep th  of tum or infil­
tration (tum or stage); the presence of positive
lym ph nodes and d istant m etastases; a n d  the  
histologic tum or type .14 Therefore, exact s tag ­
ing is imperative. To describe local tu m o r 
extension (T), presence of ly m p h  nodes  (N), 
and  distant m etastases (M), the U nion  In te r­
nationale Contre le Cancer p ro p o se d  a  un i­
form  clinical staging m ethod  (Fig. 1  and  Table
l ) . 14 Table 1 also presents the  A m erican  classi­
fication, know n as Jew ett-Strong.u
In superficial tum ors, those  w ith o u t m uscle  
invasion (stage Ta, T l, o r  carcinom a in situ), 
patients are treated  w ith  local endoscopic  re­
section w ith  or w ithou t ad juvan t in travesical 
instillations. Patients w ith  a tum or invad ing  
the muscle layer of the b la d d e r  w ail or w ith  
only m inim al perivesical extension  (stage T2, 
T3a, or m inim al T3b) are selected for rad ical 
lym phadenectom y and cystectom y or ra d io ­
therapy after neoad juvan t chem otherapy . If 
the local tum or is in  an ad v an ced  stage (stage 
T3b, T4a, or T4b), or if n o d a l or d is tan t m etas­
tases are present, the initial trea tm en t is p a l­
liative chem otherapy or rad ia tio n  therapy . If 
in  such a patient ad juvant surgical th e rap y  is 
considered, m onitoring the response  to che­
m otherapy or rad io therapy  an d  de term in ing  
the final oLitcome are im portan t.
Because clinical staging is n o t reliable for 
d e te rm in in g  tu m o r  ex ten s io n  b e y o n d  the  
b ladder wall , 12' 14 other m e th o d s  are  needed . 
In the field of imaging, rap id  changes' occur.
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Figure 1. T stages of urinary bladder cancer extension.
After the developm ent of CT scanning and  
ultrasonography, MR imaging has matured* 
Since the introduction of this technique, sev- 
eral reports in the late 1980s and early 1990s 
show ed  the superiority of this technique for
Table 1. COMPARISON BETWEEN TNM 
CLASSIFICATION AND JEWETT-STRONG STAGING 
SYSTEM
Jewett-Strong TNM Histopathologic Findings
0 TO No tumor
0 Tis Carcinoma in situ
0 Ta Papillary tumor, confined to 
epithelium (=  mucosa)
A T1 Tumor invades subepithelial 
connective tissue 
(=  lamina propria)
B1 T2 Tumor invades superficial 
muscle (inner half)
B2 T3a Tumor invades deep muscle 
(outer half)
C T3b Tumor invades perivesical fat
D1 T4a Tumor invades surrounding 
organs
D1 T4b Tumor invades pelvic or 
abdominal wall
D1 N1-3 Pelvic lymph-node 
metastases
D2 M1 Distant metastases
D2 N4 Lymph-node metastases 
above the bifurcation
staging u rinary  b ladder carcinoma.2' 3y 7~9, n_u 
15-18,23,25,31 j?ven now, the end  of rapid techno­
logic im provem ents in MR imaging is not in 
sight, and  visualization of the bladder and of 
b la d d e r  carc inom a is expected  to improve 
still further. This article describes the appear­
ance of M R images of the norm al and abnor­
mal u rinary  bladder. The role of MR imaging 
in staging this disease and in monitoring ther­
apy is review ed and  illustrated. Finally, the 
authors p resen t an overview of current and 
future applications of this technique.
MR IMAGING ANATOMY
The b ladder wall consists of four layers: 
(1 ) the m ucosa or epithelium , (2 ) the lamina 
propria  or subepithelial connective tissue, (3) 
the m uscle layer, and  (4) the serosa. The mus­
cle layer consists of bundles of smooth muscle 
tissue and  has an intermediate-signal inten­
sity, equal to that of skeletal muscle, on Tl- 
w eighted images and  a low-signal intensity 
on T2-weighted images. According to Narumi 
et al ,20 the m uscular wall consists of two dif­
ferent layers. The muscle fibers of the outer 
layer are looser and are interspersed with 
loose collagen fibers, blood vessels, and adi­
WHAT IS NEW IN BLADDER CANCER. IMAGING 585
pose tissue. Therefore, on T2-w eighted  in 
vitro MR images, the signal intensities of the 
outer bladder wall are higher. These findings, 
however, have been reported only on in vivo 
MR images in cases of b ladder wall hypertro­
phy. At the site of the trigone, the wall con­
sists of an extra triangular layer of muscle. 
Bundles from this layer link the ureteric ostia, 
forming the interureteric riclge. The serosa is 
not a bona fide layer bu t is merely a perito­
neal covering, which., in fact, is in contact 
with the bladder only a t the dome, which is 
just a small part of the entire bladder surface. 
The serosa is too thin to he recognized on 
MR images.
On T.1 -weighted, images, urine has a low- 
signal intensity, whereas the perivesical fat 
has a high-signal intensity. Because urinary 
b 1 acl cler ca rc in om as ha v e a n in te rmed ia te-sig- 
nal intensity, equal, to that of muscle, Tl~ 
weighted images are used to determine tu­
mor infiltration into the perivesical, fat (Fig.
2 ) and to show the endoluminal tumor com­
ponent. T1-weighted images are also most 
suitable for imaging lymph nodes, the signal 
intensity of which is lower than that of the 
surrounding fatty tissue. Normal and abnor­
mal lymph nodes, however, show no differ­
ence in signal in tensity  on these images. 
Therefore, a normal lymph node on MR im­
ages can be defined only by  its size and  
shape. The signal intensity of bone marrow 
métastasés is equal to that of the primary 
tumor; therefore, T1 -w eigh ted  im ages, on 
which there is a good contrast between these 
métastasés and the surrounding  fatty bone 
marrow, are best for recognizing bone m ar­
row métastasés.
On T2~ weigh ted images, the perivesical fat 
has a low- or a h igh-signal in tensity , d e ­
pending on the type of sequence used. Urine 
has a high-signal intensity. The tum or has 
an intermediate-signal intensity, higher than 
bladder wall or fibrosis and lower than urine. 
The zonal anatomy of prostate or uterus and  
vagina also can be well recognized on these 
images. These images are used for de term in­
ing d ep th  of tu m o r  infiltration w ith in  the 
bladder wall (Figs. 3 and 4); for differentiat­
ing tumor from fibrosis; for assessment of 
invasion into the prostate/ uterus, or vagina; 
and for confirming bone marrow métastasés 
seen on Tl-weightecl. images.
After intravenous administration of a g a d o ­
linium contrast agent urinary b ladder cancer 
shows earlier and greater enhancem ent than
does normal bladder wall or other n o n m a lig­
nant tissues (Fig, 5 ) > ‘to, 2). 22, 24. 27, no F urther­
more, enhancement occurs earlier in b ladder 
cancer than in edema and granulation tissue.s
F igure  2. Axial T 1 -weighted three-dimensional MP-RAGE image 
in a patient with stage T3b urinary bladder cancer. Tumor infil­
trates the perivesical fat (arrows) up to pelvic piriform muscle.
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Figure 5. Same patient as in Figure 2 with infiltrative {stage T3b) urinary bladder cancer. A, Coronal 
T1-weighted unenhanced image shows tumor infiltration in perivesical fat (arrows). B, Enhanced T1- 
weighted image in same plane, and C, subtraction of A and B shows more enhancement of tumor 
(arrows) than of surrounding tissues; therefore, tumor is more visible. Central lack of enhancement 
is caused by necrosis (n).
STAGING
MR imaging is unsuitable for diagnostic 
screening for bladder cancer because of its 
high cost, and cystoscopy remains the most 
appropriate m ethod of detecting a bladder 
tumor. Once a b lad d er  tum or is detected, 
staging is needed to plan therapy and prog­
nosis. Most important in this regard is the 
d istinction  betw een  superficial tum ors and 
tumors invading the muscular bladder wall.
best technique for separating superficial tu­
mors (stage T'l) from, minimally invasive tu­
mors (stage T2).‘tJ' 26 Transurethral resection 
also offers information about tum or histol­
ogy. Currently, with MR imaging, differentia­
tion of stage T1 from stage T2 is difficult. 
Therefore, staging usually begins with trans­
resection.
resection and bimanual examination, is the
Patients with superficial tum ors are treated 
with local endoscopic resection followed by 
intravesical instillations of chemotherapeutic 
agents, BCG therapy, or both. In these pa­
tients, no additional staging procedures  are
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n e e d e d . A n  excep tion  could be m ade for 
s ta g e  T1 tu m o rs  w ith  a h igh  m alignancy 
g rad e  (grade III), because these tumors have 
a h ig h  likelihood of progressing to an infil­
tra tive  tum or or of metastasizing.
Patien ts  w ith  m uscle invasion, with per­
ives ica l in filtra tion , or w ith  invasion  into 
prosta te , vagina, o r u terus (stages T2~T4a) 
m ay  undergo  radical lym phadenectom y and 
cystectomy. W hen pelvic side wall infiltration 
or tu m o r extension into the abdominal wall 
(stage T4b) or m etas tases are present, alone 
or in  combination, surgery usually is not the 
first choice. Instead, neoadjuvant chemother­
apy  o r  p a llia tiv e  ra d ia tio n  th e rap y  is p re ­
scribed. Therefore, preoperative recognition 
of pe lv ic  side w all infiltration or metastases 
is im p o r ta n t  Because the accuracy of clinical 
s ta g in g  in  th is  m a tte r  is unreliable , other 
m eth o d s  are required, CT scan seems to be a 
valuable  add ition  in this setting. The overall 
p r im a ry  staging accuracy ranges from 40% to 
92% (mean, 74%).2' 3' 7~9' 13' 17' 18' ^ 25 The accu­
racy of MR im aging  for prim ary tum or stag­
ing varies from  73% to 96% (mean, 85%), 
T hese values are 10% to 33% (mean, 19%) 
h ig h e r  th a n  those  ob ta ined  w ith  CT scan. 
Published  da ta  on  the accuracy of MR im- 
ag in g  com pared w ith  that of CT scan for stag­
ing tu m o r and  lym ph node metastases are 
su m m arized  in Table 2 .
I n  staging ly m p h  node metastases, MR im ­
ag in g  and CT scan are comparable w hen two­
dim ensional techniques are used; accuracy for 
CT scan is 83% to 97% (mean, 89%) versus 
73% to 98% (mean, 89%) for MR imaging. 
W ith  n e w  th ree -d im en sio n a l techniques, 
how ever, MR im aging results are promising 
(accuracy, 90%) (Jager GJ, Barentsz JO, Oost- 
erhof GO, et al, unpublished  d a ta ) . 4 Finally, 
MR im aging seems to have advantages over 
CT scan and nuclear bone scanning in  the 
diagnosis of bone m arrow  metastases (Fig. 
6 ) . 1' 3
M uch interest has been generated by  the 
possibility of using MR im aging to differenti­
ate betw een superficial (stage T2) and deep 
invasion of the muscle layer of the bladder 
wall (stage T3a). W ith clinical staging, CT 
scan, and intravesical sonography, this dis­
tinction cannot be m ade reliably. Most p u b ­
lished reports indicate that these stages can 
be differentiated on unenhanced T2 -weighted 
im ages ,3,9> n*25, 31 More recently, Nicolas et 
al, 24 Tachibana et al , 29 and Sparenberg et al ,28 
show ed that the extent of invasion in  the 
b ladder wall is better delineated on postcon­
tras t T l-w e ig h ted  im ages th an  on u n e n ­
hanced T2-weighted images. From  a clinical 
point of view, however, distinguishing be­
tween stage T2 and  stage T3a tum ors is rather 
unim portant.
For differentiation betw een m uscular inva­
sion (stage T3a) and invasion into the perives­
ical fat (stage T3b), results of MR im aging are 
equal to2' 1 3 /18 or slightly better than3' 8/ 9> Ur 25
Table  2. REPORTED STAGING RESULTS WITH MR IMAGING AND CT SCAN FOR TUMOR AND NODE STAGING
Reference
Number
Patients
Correct
Staging
of
Tumors
<%)
Correct 
Staging 
of Nodes
(%)
Contrast
Material
Number
Patients
Correct 
Staging 
of Tumor
(%)
Correct 
Staging 
of Nodes
(%)
Contrast
Material
Fisher et al11 12 64 none 14 85 none
Beyer et al7 --- -- --- ------------ 26 80 73 none
Amendola et al2 10 40 90 IV, oral 11 73 91 none
KOper et al10 15 ------------ ------------ IV 12 75 none
Bryan et al8 9 67 89 IV, oral 10 80 90 none
Rholl et al25 19 85 95 IV 23 96 96 none
Nicolas et al23 161 82 ------------ IV, oral, rectal 13 92 M none
Buy et al9 30 60 97 — 0 83 98 none
Koebel et al17 ------------- --- ------------ ------------ 10 90 none
Husband et al13 30 80 ------------ IV, oral, rectal 30 73 none
Barentsz et al3 60 45 82 oral, recta! 60 85 96 none
Tavares et al31 34 ------------ ------------ ------------ 34 91 none
Tachibana et aP 57 72 ------------ IV 57 91 IV
Kim et al16 36 55 ------------ IV 36 75 -
n  w
IV
Barentsz et al4 ------------- ----------- ------------ ------------ 28 93 93 IV
Barentsz et al5 ------------- ------------ ------------ ------------ 61 84 93 IV
Dash Indicates data not reported. IV = intravenous.
WHAT IS NEW IN BLADDER CANCER IMAGING 589
those of CT scan. In  m ost centers, however, 
patients w ith  stage T3a and stage T3b tumors 
are treated w ith  cystectomy.
Besides difficulties in  distinguishing stage 
T1 tumors from stage T2 tumors, MR imaging 
has other limitations. A lthough differentia­
tion betw een late fibrosis and  granulation tis­
sue and carcinoma is better w ith MR imaging 
than w ith CT scan an d  ultrasound, differenti­
a tion  b e tw een  acu te  edem a or hyperem ia , 
present during  the first weeks after transure­
thral resection, and tum or is difficult.6,10' 21' 22' 
24, 28,29 Therefore, staging after transurethral 
resection is som ew hat inaccurate. This p rob­
lem  m ay be solved by using ultrafast dy ­
namic sequences .5 A n  alternative is to per­
fo rm  MR im ag in g  before tran su re th ra l 
resection. This strategy, however, results in 
unnecessary M R im aging examinations in all 
patients w ith  superficial tumors, w ho make 
up  two thirds of all patients w ith  urinary 
b ladder cancer. Taking into account the high 
cost and the lim ited availability of MR im ­
aging time for abdom inal studies, this ap ­
p ro ach  does n o t seem  acceptable for the 
health  care system.
On the basis of published reports and the 
authors ' ow n experience, Table 3 offers an 
overview of the value of the several staging 
techniques for u rinary  b ladder cancer. MR 
im ag ing  an d  clinical s tag ing  com plem ent 
each other. MR im aging is the most accurate 
technique for differentiating between various 
stages of deeply infiltrating tumors (stages T2 
and  higher), w hereas clinical staging is the 
b es t techn ique  for d ifferen tia ting  be tw een  
acute edema, early granulation tissue, and the 
various stages of superficial tumors (stages
low er than  T2). W hen  MR im aging  is avail­
able, CT scan is not needed .
NEW DEVELOPMENTS
Rapid im provem ents in h a rd w a re  a n d  soft­
ware, innovations in  contrast agents, an d  the  
use of MR im ag ing -gu ided  b io p sy  m ak e  MR 
im aging an increasingly pow erftil tool for ra ­
diologists and  urologists.
Surface Coils
W ith new  phased-array  surface coils, a se­
ries of T2-weiglited high-re so lu tion  im ages 
can be m ade in  5 m inu tes (see Fig. 4). For 
evaluating the extent of m uscle invasion , the 
combination of an  external p h ased -a rray  an d  
an endorectal coil w ith  these pu lse  sequences 
seems promising.
Three-dimensional Sequences
At the present, a three-d im ensional d a ta  set 
can be obtained w ith in  a sho rt time. W ith  the 
help of fast postprocessing techniques, such 
as m ultip lanar reconstruction, im ages can  be 
reconstructed in every desired plane. The use 
of m ultip lanar reconstruction im proves local 
tum or stag ing .4 Local tum or grow th , ad h e­
sions and  bow el w all invasion, an d  bone m ar­
row  m etastases can be  visualized be tter than  
w ith conventional tw o-d im ensional M R im ­
aging techniques. In a series of 28 patien ts, 
accuracy of p rim ary  staging im p ro v ed  from
Table 3. ACCURACY OF DIFFERENT STAGING TECHNIQUES
Differentiation
Clinical Staging 
Including
Transurethral
Resection
Intravesical
Sonography
CT
Scan
MR
Imaging
T0-T + + + --- 4-
Tis-T a + + --- —
Ta~T1 + + --- —
T1-T2 + + --- 0
T2~T3a 0 0/ + ---
T3a-T3b — 0 + + +  +
T3b-T4a — 0 + + +
T4a-T4b — — + + +
N0-N + — — + +
MO-M + * — — 0/ + +  +
*Bone marrow infiltration.
TO = no malignancy (e.g., scar, fibrosis, granulation tissue, hypertrophy); T 4- = malignancy; + +  = highly accurate; + -  accurate; 
0 = not accurate; — = not possible.
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Figure 6. Patient with infiltrative (stage T3a) urinary bladder cancer with bone marrow métastasés. 
A, Semicoronal reconstructed spiral CT scan of lumbar spine (posterior view) does not show métasta­
sés. B, Bone scintigram of spine prospectively shows only minimally increased uptake in the lumbar 
region. C, On T1-weighted sagittal MR image, areas of low-signal intensity are present in the thoracic 
(arrow) and lumbar (open arrows) spine, which enhances on (D) postcontrast image and shows high 
signal intensity on (F) gradient echo T2-weighted image. Enhancement is more prominent on (E) 
subtraction of C and D. These findings are suggestive of métastasés and were confirmed by clinical 
follow-up. Retrospectively, B shows lack of uptake at the site of the métastasés in the thoracic
spine (circle).
Illustration continued on opposite page
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78% to 93°/o. Also with this technique, three- 
d im ensional inform ation concerning lymph 
nodes can be obtained. Normal nodes mea­
suring 3 mm can be recognized, because the 
three-dimensional technique shows the size 
and shape of nodes. The maximal length and 
the axial size can be determined quantita­
tively, and round nodes can be distinguished 
from oval nodes by dividing the axial size by 
the length. Lymph nodes are considered to 
be enlarged pathologically when the index is 
more than 0.8 for a round node with a mini­
mal axial size of 8 mm or more (Fig. 7), or 
w hen the index is less than 0.8 for an oval 
node with a minimal axial size of 10 mm or 
more (Fig. 8). An asymmetric cluster of small 
lymph nodes also is considered to be patho­
logic. W hen using these criteria in 134 pa­
tients with bladder (n = 71) or prostate can­
cer (n = 63), an accuracy of 90%, a specificity 
of 98%, a sensitivity of 75%, and a positive 
predic tive  va lue  of 94% can be achieved 
(Jager GJ, Barents?, JO, Oosterhof GO, et al, 
unpublished data). Correct identification of 
pathologic nodes was possible in 33 cases; 
however, microscopic metastatic deposits in 
normal-sized nodes were not recognized in 11 
patients. In only two patients with enlarged 
nodes without metastasis, a false-positive di­
agnosis w as obtained. These results show that 
three-dimensional MR imaging can be used 
to select pa tien ts  for MR im aging- or CT
scan-guided biopsy or laparoscopic perito­
neal lymph node dissection.
Fast Dynamic Imaging
Urinary bladder cancer shows more and 
faster enhancem ent than b ladder after 
injection of MR imaging contrast agents, 
probably because of tu m o r  neovascularity . 
Fast dynamic sequences (one image per sec­
ond) allow evaluation of minimal differences 
in enhancement of bladder cancer and other 
structures. U rinary  b lad d e r  cancer shows 
early enhancement beginning about 6 seconds 
after the initiation of arterial enhancement; 
the urinary bladder enhances about 4 seconds 
earlier than most other structures, including 
postbiopsy tissue. In a series of 61 patients, 
based on the beginning of enhancement, im­
proved accuracy (from 79% to 90%) and spec­
ificity (from 33'% to 92%) were obtained in 
differentiating postbiopsy tissue from malig­
nancy. Overall accuracy of tum or staging 
im proved  significantly, from 67% to 84% 
(p<0.01).5
Métastasés in en larged  or norm al-sized  
lymph, nodes may show early enhancement, 
equal to that of the primary bladder tumor 
(Fig. 9); therefore, recognition of métastasés in 
normal-sized nodes may be possible. Current 
limitations of this technique, such as the in­
ability to image at more than one level with
Text continued on page 599
Figure 7. Patient with infiltrative (stage T2) urinary bladder cancer and nodal metastases. A, T1- 
weighted MP-RAGE image in plane parallel to right iliac vessels (v = vein; a = artery) shows lymph 
node with length of 10 mm (circle). B, T1-weighted reconstructed plane perpendicular to longitudinal 
axis of node shows axial size of 9 mm. index is 0.9, which suggests a round node; therefore, the 
axial size of 9 mm is abnormal. Histology confirmed metastases.
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Figure 9. Patient with infiltrative (stage T3b) urinary bladder cancer (arrows) 
with metastatic node (circle). A, T1-weighted coronal MP-RAGE image 
shows enlarged node (23 x  16 mm). B, Subtracted maximal-signal-intensity 
image displays maximal enhancement in black. Node (circle) and tumor 
(arrows) show the most enhancement.
Illustration continued on opposite page
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Figure 9 (Continued). C, On time image, start of enhancement in relation 
to onset of arterial enhancement is color coded. Color could not be printed 
so black-and-white scale is used. Every tone represents 1.25 seconds. 
White is t -  0 seconds; black is t >  10 seconds (for scale see Fig. 9). 
Node (circle) and tumor (arrows) start to enhance within 10 seconds after 
the artery, indicating malignancy. D, On slope image, maximal enhancement 
rate is color coded. Cranial part of node (open arrow) and central part of 
tumor (arrows) show high enhancement rate.
Illustration continued on following page
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Figure 9 (Continued). Three-dimensional reconstructions of MP-RAGE data 
parts E  and F  show vessels as dark, bladder lumen as speckled, and 
enlarged (circle) and normal-sized node (arrow) as darker speckled. Poste­
rior view (E) and left posterior oblique view (F) (P posterior; A = anterior; 
R = right; L = left).
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Figure 9 (Continued). Axial (G) and angulated (H) sagittal T1 -weighted SE 
images during MR-guided biopsy. Needle is visible as black line. Needle tip is at 
site of node (arrow). The biopsy confirmed metastasis, and the patient had 
chemotherapy.
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Figure 9 (Continued). /, Coronal MP-RAGE image after chemotherapy, 
identical to A, shows decrease of nodal (circle) and tumor size. J, Time 
image in same plane as A, C, and I after chemotherapy shows dark color 
of node and tumor, meaning late enhancement. Compared with C, enhance­
ment is at least 18 seconds later; this difference is explained by decrease 
of tumor neovascularity because of response to chemotherapy,
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this high speed, will be overcome in the fu­
ture. Initial experim ents already show that 
fast dynamic im aging is possible at four lev­
els (Fig. 10).
These fast dynam ic sequences after adm in­
istration of MR im aging contrast material are 
also useful in the evaluation of chemotherapy 
in patients w ith  urinary  b ladder cancer. Initial 
results in 16 patients who received 3 X 2  
MVAC chem otherapy treatments showed a 
reduction of tum or size on conventional un­
enhanced MR im ages in  10 patients (see Figs, 
9A  and I). This correlated w ith a response in 
eight patients and  no response in two. In six 
patients, no decrease in  tum or size w as visi­
b le  on conven tiona l MR im ages; how ever, 
two of these patients had  complete response. 
In  10 p a tien ts , fast dynam ic techniques 
show ed  de layed  tu m o r  enhancem en t after 
only two MVAC treatments. In these patients, 
tum or enhancem ent started later than  1 0  sec­
onds after arterial enhancement, whereas be­
fore chem otherapy all tum ors started to en­
hance within 6  seconds. In all 10 of these 
patients, response to the chemotherapy oc­
curred (see Figs. 9C and  9ƒ). In the remaining 
6  patients, the enhancem ent persisted to be 
early, which correlated w ith  no response.
Postprocessing
Progress in com puter technology will result 
in  innovations in  the postprocessing of the 
acqu ired  data . Fast m u ltip lan a r  im aging 
allows evaluation of three-dimensional data 
sets in every plane. Three-dimensional seg­
m entation techniques facilitate better visual­
ization and understand ing  of the spatial rela­
tionsh ip  b e tw een  n o rm a l and  abnorm al 
structures (see Figs. 9E and 9F). With the help 
of maximal intensity projections, vessels can 
be  v isua lized  w ith o u t  the use of contrast 
agents. O ther te cliniques show quantitative 
information about time, slope, and w ashout 
of tu m o r en h an cem en t in  color, p ro jected  
over the original images (see Figs. 923, 9C, 
and  9D).
MR Imaging-guided Biopsy
The goal is to obtain a histologic diagnosis 
by  as noninvasive a procedure as possible. 
This can be achieved by  image-guided biops­
ies. At the present time, these biopsies are 
perform ed under the guidance of fluoros­
copy, u ltrasonography, or CT scan. Because 
of time constraints on MR im ag ing  scanners, 
MR imaging guidance for biopsies is no t used  
frequently . N ev e r th e le ss , M R  im a g in g  also  
has advantages over other im ag ing  m o d a l­
ities in  this respect. M R im aging is a three- 
d im ensiona l im ag in g  techn ique ; th e re fo re , 
m ultiple angulated  biopsies can  be perfo rm ed  
best under MR im aging  guidance. A good 
example in b ladder cancer is the th ree-d im en­
sional visualization of enlarged ly m p h  nodes 
and subsequent MR im ag in g -g u id ed  b iopsy  
(see Figs. 9G and  9H). In  a p re lim inary  s tudy , 
the authors perfo rm ed  MR im ag in g -g u id ed  
biopsies in  1 2  patients w ith slightly  en larged  
nodes; in 9 of the 12 patients, the b iopsy  
yielded true positive results. These positive 
biopsy results obviated the need  for lym ph- 
node dissection. A nother advan tage  of con- 
trast-enhanced MR im aging is th a t its speci­
ficity an d  sen s itiv ity  in  s h o w in g  u r in a ry  
b ladder cancer and possible m etastases are 
higher than  those of u ltrasonography  a n d  CT 
scanning. According to  the enhancem en t p a t­
tern of the tum or, w ith  MR im ag ing  the p a r t  
of the tum or tha t contains the greatest n u m ­
ber of abnorm al vessels, and  therefore the 
m ost viable p a rt of the tum or, can  be local­
ized and  biopsied.
At present, specially designed M R im aging 
units are being developed to  sim plify local­
ization under MR im aging gu idance  a n d  to 
reduce biopsy time. W ith  regular M R im aging 
machines, biopsies m u s t be perfo rm ed  in  the 
same w ay  they are perfo rm ed  w ith  CT scan. 
Special n o n m ag n e tic  n e e d le s  are  ava ilab le ; 
however, efforts m ust be  m ade fu rther to  re­
duce susceptibility artifacts caused  by these 
needles.
In the near future, fast, h igh-resolution, dy­
namic contrast-enhanced MR im aging  of the 
urinary  b ladder will further im prove  d iag n o ­
sis, staging, and  follow-up in pa tien ts  w ith  
urinary  b ladder cancer. Therefore, this tech­
nique will be used  m ore and m ore frequently  
in these patients. MR im ag in g -g u id ed  b iopsy  
will contribute to a less invasive diagnosis, 
thereby im proving treatm ent p lanning .
CONCLUSION
At present, MR im aging is the m o d a lity  of 
first choice for im aging the u r in a ry  b lad d e r  
and urinary b ladder cancer. Becaiise of the 
limited resources of the  health  care system , 
however, this technique should  be  u sed  only 
to obtain information tha t directly influences
nam
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Figure 10. See legend on opposite page
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the therapeutic m anagem ent and outcome. To 
obtain this goal knowledge of urologists of 
MR im aging an d  knowledge of radiologists 
of clinical m anagem ent are needed; therefore, 
continuous education and communication be­
tw een these tw o  specialties is a necessity.
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